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Patient’s treatment plan verification covers substantial amount of the quality assurance 
(QA) resources; this is especially true for Intensity-Modulated Proton Therapy (IMPT). The 
use of Monte Carlo (MC) simulations in supporting QA has been widely discussed, and 
several methods have been proposed. In this paper, we studied an alternative approach 
from the one being currently applied clinically at Centro Nazionale di Adroterapia 
Oncologica (CNAO). We reanalyzed the previously published data (Molinelli et al. (1)), 
where 9 patient plans were investigated in which the warning QA threshold of 3% mean 
dose deviation was crossed. The possibility that these differences between measurement 
and calculated dose were related to dose modeling (Treatment Planning Systems (TPS) 
vs. MC), limitations on dose delivery system, or detectors mispositioning was originally 
explored, but other factors, such as the geometric description of the detectors, were not 
ruled out. For the purpose of this work, we compared ionization chambers’ measure-
ments with different MC simulation results. It was also studied that some physical effects 
were introduced by this new approach, for example, inter-detector interference and the 
delta ray thresholds. The simulations accounting for a detailed geometry typically are 
superior (statistical difference – p-value around 0.01) to most of the MC simulations used 
at CNAO (only inferior to the shift approach used). No real improvement was observed in 
reducing the current delta ray threshold used (100 keV), and no significant interference 
between ion chambers in the phantom were detected (p-value 0.81). In conclusion, 
it was observed that the detailed geometrical description improves the agreement 
between measurement and MC calculations in some cases. But in other cases, position 
uncertainty represents the dominant uncertainty. The inter-chamber disturbance was 
not detected for the therapeutic protons energies, and the results from the current delta 
threshold are acceptable for MC simulations in IMPT.
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1. inTrODUcTiOn
Delivering an appropriate radiation therapy dose starts by preparing the most suitable treatment 
plan for each patient. This is done by conforming the delivered dose to the clinical target volume 
and avoiding critical organs (2) in order to limit the observed side effects on the surrounding tissue 
in the patient. Proton beams, with their defined range, can play an important part in increasing 
FigUre 1 | cnaO patient plan verification results for the nine cases above the warning threshold (6). For each data set exceeding the warning level, the 
mean absolute deviation is plotted. Measurements are compared to four different scenarios of calculated values: ● – TPS calculated dose, ▲ – MC simulated dose 
based on treatment plan data, Δ – MC simulated dose based on DDS log files, and ◊ – MC simulated dose based on DDS log files and corrected for the optimal 
3D holder shift. For the last case, the applied translation vector, expressed in millimeters, is also reported between brackets.
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this conformity (3). Monte Carlo (MC) simulations are one of the 
proposed three different dose calculation algorithms, alongside 
ray trace and pencil beam. Although MC has been considered 
the gold standard between these approaches in respect to its 
accuracy, pencil beam model is mostly used in the treatment 
plan system (TPS) due to its compromise between accuracy and 
computational time.
After finding the best solution for how to deliver the dose, a 
verification process is needed in order to check if the equipment is 
able to deliver the planned treatment fields. Several methods have 
been proposed, such as the ones by PSI (4) and MD Anderson (5), 
but at Italian National Center for Oncological Hadron Therapy 
(CNAO), the method developed by GSI and used at HIT (1, 6), 
is adopted. CNAO is a hospital-based hadrontherapy facility 
equipped with a custom synchrotron and Dose Delivery System 
(DDS) to provide actively scanned proton beams with energies of 
62–227 MeV/u and carbon with 115–400 MeV/u, corresponding 
to ranges in water of 3–32 and 3–27 cm for protons and carbon 
ions, respectively (7).
Individual treatment plan verifications in the experimental 
environment can be very time and manpower intensive, and it is 
prone to dose delivery uncertainties and setup errors. Molinelli 
et al. (1) presented CNAO’s quality assurance results for all the 
patients treatment plans verification that have been performed 
in CNAO with proton beams concerning 1  year (September 
2011–August 2012). Nine cases have been found where the qual-
ity assurance warning threshold was exceeded, which is fixed at 
3% mean absolute deviation between measurements and TPS. 
Originally, the possibility explored was that these differences 
between measurement and calculated dose were related to dose 
modeling (TPS vs. MC), limitations on DDS, or detectors mis-
positioned (shift), but other factors were not ruled out, such as 
oversimplification of the dose modeling.
FLUKA (8, 9) was the MC code chosen for this work due to its 
demonstrated capabilities (10, 11) and available powerful graphi-
cal interface (12).
In this work, we have evaluated if improvements could be 
applied to the MC simulations in order to get better agreement 
with the measured data on these previously described cases 
(Figure 1). More specifically, we studied the use of more detailed 
representation of the detectors (13, 14) and the effect of physi-
cal processes that these could introduce in the MC simulation 
results, for example, the required threshold settings for specific 
scenarios (15).
2. MaTerials anD MeThODs
2.1. TPs Patient Plan Verification
The TPS used in CNAO is the CE-marked syngo® RT Planning 
by Siemens AG Healthcare (Erlangen, Germany) version VB10, 
which is based on TRiP98 (16, 17).
The current CNAO quality assurance procedure (1, 18) speci-
fies that for each patient, plan verification will be performed (6). 
For this, a water tank with a 3D detector block controlled by a 
motorized arm (PTW) is used. This enables to measure the depos-
ited dose at different known depths and positions. This detector 
block provides a support holder for the ionization chambers (IC), 
in such way that an individual IC do not mask the direct path 
of the beam to other the IC (PTW pin point IC – Figure 2). IC 
FigUre 2 | Different tools used in the treatment plan verification. The pin point ionization chamber (left), the 3D detector block (center), and the water tank 
with motorized arm (right) by PTW.
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measurement values are then compared with the ones calculated 
by the TPS (equation (1)). For data set analysis, the mean devia-
tion is calculated as the difference between measured (dmeasi) 
and calculated dose (dcalci), normalized to the maximum beam 
dose (dmax) and averaged over N IC positions i:
 i
N
i i
N
dmeas dcalc
dmax∑
−1 %
 (1)
The number of points, N, included in the calculation can 
be equal or lower than 12, depending on the data set. The TPS 
provides a 3D-averaged dose gradient for each IC position. Points 
with a calculated gradient higher than 0.04 Gy mm−1 are excluded 
from the analysis, since they could not be measured sufficiently 
accurately due to the finite size of the detector sensitive volume 
and experimental setup uncertainties. For QA measurements in 
reference conditions, the applied acceptance threshold is 5% for 
both mean deviation and SD over a data set.
2.2. Monte carlo simulations
FLUKA is a multipurpose MC transport code originally designed 
for high-energy physics but with extensive use in medical applica-
tions (10, 11). For the purpose of this paper, the HADROTHErapy 
suite of physical settings (known as Defaults) was selected. All 
geometry updates and modifications were completed with the aid 
of FLAIR (a graphics user interface of FLUKA).
2.2.1. Current MC-Based Plan Verification
A complete detailed description of CNAO facility, including 
accelerator design and rooms layout, can be found in the litera-
ture (1, 7). For the simulation purposes, the geometry description 
accounted for the different structures, mainly from the monitors 
of the DDS, present in the beam path. The validation of this DDS 
description with FLUKA has been described previously (1). In 
Figure 3, the photo of the end of the nozzle in one of the treatment 
rooms is shown together with its description in a 3-dimensional 
model and its description within the FLUKA simulation.
Current MC patient plan verifications, as per TPS, use a sim-
pler approach to geometrically represent the IC when calculating 
the dose deposition. All detectors’ structures and holders are not 
included, and the detector dose is sampled from the dose distri-
bution in a water tank. By doing that, the structure and materials 
of the IC are not taken into consideration for the simulation. 
MC obtains the deposited dose in the chambers by calculating 
the average dose to water over several voxels, corresponding 
to  the  active volume of the detector, situated in the positions 
where the chambers is located.
2.2.2. New Detailed Geometry
The previously described approach, with its geometric approxi-
mations and simplifications, obtained deviations below 3% for 
the majority of studied cases. But for these nine cases where the 
agreement between the TPS calculations and measurements 
was above this threshold, we decided to investigate the impact 
of using a detailed geometry in order to account for the dose 
disturbances, mainly from scattered particles produced in the 
wall of the IC and detector holder. In the new detailed geometry, 
all geometry described above is kept with the inclusion of the 
PTW3D block and IC description (respecting all structures, 
dimensions, and material compositions). Detailed technical 
drawings were obtained from the manufactures (PTW Freiburg). 
Flair geometry editor was instrumental and extremely helpful 
in dealing with drawing and 3D visualization (Figure 4). As for 
the original MC approach, the absolute mean dose deviation is 
calculated applying equation (1).
2.2.3. Delta Rays
Delta rays are defined as electrons that acquire sufficiently high 
kinetic energies through collisions so as to enable them to carry 
this energy a significant distance away from the track of the 
primary particle and produce their own ionization of absorber 
atoms (19). The FLUKA “HADROTHErapy” option uses per 
default delta ray production and transport cuts of 100 keV. We 
have chosen to vary the threshold limits in order to evaluate if the 
observed variation between measurements and FLUKA simula-
tions was influenced by the delta rays threshold value.
The dose to water was calculated by averaging the dose depos-
ited in the sensitive volume of the IC. And in order to study the 
FigUre 3 | cnaO dose delivering system can be seen in these figures. A photo of the system, a model with its components description, and the final model 
used in the Monte Carlo simulations.
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effect of the delta rays threshold, all regions surrounding the 
sensitive volume had their threshold changed. In this work, we 
studied the effect of using 10 and 1000 keV in comparison to the 
default of 100 keV.
2.2.4. Organization of This Work
In total, nine fields from different patients’ plans were analyzed, 
including MC simulations (for both described geometries) and 
dose deposition matrices from TPS and IC results (from plan 
verification quality assurance). The analysis of the data and this 
section are divided as follows:
•	 Geometry effect  –  Section 3.1: compared data obtained from 
the MC with and without the complete geometry, with experi-
mental data and TPS calculated dose values.
•	 Influence of the δ-rays thresholds – Section 3.2: compared data 
obtained from MC simulations of two different fields for differ-
ent thresholds (10, 100, and 1000 keV). For that, all regions in, 
or in direct contact with, the active volume had its threshold 
modified for the purpose of these simulations (Figure 5).
•	 Chamber–chamber effect  –  Section 3.3: at CNAO, the mea-
surements are made with half of the proposed number of the 
detectors (24); so data from MC simulations were compared 
FigUre 4 | Demonstration of the powerful tools available in Flair. On the left, the technical drawing superimposed on the generated geometry is shown, 
and on the right, the final geometry of the phantom in 4 different views is reported.
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with two different setups, one with all 24 IC versus the same 
setup with 12 IC.
3. resUlTs
3.1. The influence of a Detailed geometry 
implementation
In Figure 6, it was compared for each data set results obtained 
implementing detailed geometry, Section 2.2.4, in relation to the 
ones obtained by Molinelli et al. (1).
An advantage was noticed when using a more detailed 
geometry (MC-NGeo-DDS), as it can be seen by the 6 cases 
where better results were obtained in comparison to the previous 
MC-DDS (MC simulations based on DDS log files). In order to 
understand if the difference between these MC simulations and if 
the measurements are significant, the relative difference between 
MC and measurements was calculated and analyzed.
A p-value of 0.003 was obtained between MC-DDS (current 
MC geometry description) and MC-NGeo-DDS (more detailed 
geometry description) by using a 2-tailed t-test, which describes 
that the obtained results by the more detailed geometry approach 
are significantly better in relation to the current MC Geometry 
description.
3.2. The influence of Delta rays Threshold
The effect in the absorbed dose and computational time was ana-
lyzed for two patients’ data sets with different δ-ray thresholds. 
As described previously, in Section 2.2, with FLUKA MC code, 
the user is able to set different thresholds for both production 
and transport of different particles. Initially as expected, some 
differences were noted between the individual measurements for 
each threshold and comparison to the current default threshold, 
set at 100 keV (Figure 7). When compared to the measurements 
individually and as data set (Figure 7), no comparable advantage 
was noticed by using different thresholds.
When comparing the computational time when the δ-ray 
threshold is changed, it was observed that by increasing the 
threshold (from 100 to 1000 keV), the average time to simulate 
all primaries reduced by 11.45 ± 3.39%, and when the threshold 
was reduced (from 100 to 10 keV), the average time to simulate 
all primaries increased by 43.49 ± 22.02%.
3.3. chamber–chamber effect
Another aspect analyzed was the fact that instead of using the 
full 24 positions available in the ionization chambers holder (see 
Figure 4), only 12 positions were used, allowing for investigating 
the influence of chamber–chamber effect. A 2-tailed t-test was 
performed, as in Section 3.1, and no statistical significant differ-
ence (p-value 0.996) was found between both simulations with 12 
or 24 chambers. Figure 8 shows the calculated deviations for the 
different data sets for both MC and TPS.
4. DiscUssiOn
4.1. The influence of a Detailed geometry
In this work, we evaluated the effect of the IC geometry description 
in MC simulation for patient plan verification. We compared our 
geometrical description with the current approach used. Figure 6 
showed that by improving the details of the detectors geometry 
description, on average, we obtained a mean deviation of 1.90% 
with 0.63% 1 SD for the 9 cases in comparison to the current 
method (1), which obtained a mean deviation of 2.36% (0.75%).
Another source of uncertainty is the positioning of the phan-
tom. In order to evaluate if the deviations found were introduced 
not only by the MC simulations but also by the position of these 
detectors during measurements, we simulate the effect of intro-
ducing this uncertainty.
We simulated different detector positions within ±1 mm in all 
direction for one of the data set (Data Set 2) around the original 
position, in total, 27 positions miming uncertainties in the detec-
tor positioning. A new minimum of 1.94% was found at (1, −1, 1) 
as dx, dy, and dz, respectively, in comparison to 2.40% as reported 
by Molinelli et al. (1).
The obtained mean deviation in respect to the applied offset can 
be seen in Figure 9. It can be seen that the obtained deviation varies 
with the positioning of the detector block in a systematic manner, 
FigUre 6 | results for the effects of different approaches when performing patient plan verification in relation to geometry description.
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where a minimum and a maximum deviation can be obtained by 
optimizing the detector position. This also shows that for this data 
set, the importance of a proper positioning of the water phantom.
4.2. chamber–chamber effect
In addition to the benefits of using a more detailed geometry 
description, additional points needed to be evaluated as possible 
contribution to errors and uncertainties. The first one was the 
interference seen by a detector from the interaction of beam to 
previously positioned detectors. Although this effect had been 
evaluated for carbon ions (20) in the case of protons which are 
more susceptible to the broadening, it had not been evaluated. 
In our study, no significant difference was seen between the 
measurements with and without the extra detectors.
4.3. The influence of Delta rays Threshold
Another possible factor which will influence the MC simulation 
results with more detailed detector geometry is the choice of 
delta rays threshold. For this reason, we evaluated threshold in 
our detailed geometry. We found that current thresholds used by 
FigUre 5 | Flair representation of internal structures of the ionization chamber. The detector active volume is labeled as “IC10fil” for the IC number 10. All 
regions in, or in direct contact with, the active volume had its threshold modified for the purpose of these simulations.
FigUre 7 | results for the effects of different delta rays thresholds in the more detailed geometry Mc simulations for data sets 1 and 2. It is plotted as 
the comparison between measurements and MC with different thresholds for the two cases (left) and their obtained deviations in respect to measurements (right).
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FigUre 8 | calculated differences between simulation with 12 and 24 
ionization chambers. The figure on the left shows the different deviation for 
each IC measurement for all the data sets. The figure on the right shows the 
obtained histogram of these deviations.
FigUre 9 | results for the obtained mean deviation in respect to the 
applied offset. The color bar represents the mean average deviation 
obtained in %.
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the default, which have been previously analyzed (11), are still 
sufficient for this detailed geometry, and no improvement was 
observed by the reduction of these.
5. cOnclUsiOn
The use of MC simulations in aiding patient plan verification has 
been evaluated. In this work, we studied the effect of improving the 
detectors geometry description in the MC simulations. We showed 
that even in the most challenging scenarios of very non-uniform 
fields, a more detailed geometric description of the detectors results 
in better agreement with the measurements, although at the cost 
of more computational time (18.8% in average). If taken into con-
siderations that only 9 patient in an entire year period crossed the 
threshold, this increase of time should not limit the use of a more 
detailed geometry description. Additionally, we saw that for few 
cases where the uncertainty of mispositioning was more relevant 
than the modeling uncertainties, the use of detailed geometry 
description in the MC simulation was not able to improve agree-
ment with measurements. For these cases, it was only possible to 
obtain a better agreement after the detector position was shifted.
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